Definitive Healthcare (NASDAQ:DH) Trading 1.8% Higher - Here's What Happened

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) shot up 1.8% during trading on Wednesday . The stock traded as high as $4.05 and last traded at $4.02. 687,326 shares changed hands during mid-day trading, a decline of 15% from the average session volume of 807,743 shares. The stock had previously closed at $3.95.

Analysts Set New Price Targets

Several brokerages recently commented on DH. The Goldman Sachs Group boosted their price target on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research note on Monday, May 12th. BTIG Research downgraded Definitive Healthcare from a "buy" rating to a "neutral" rating in a report on Friday, May 9th. Finally, Wall Street Zen upgraded Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $5.10.

Definitive Healthcare Trading Down 4.5%

The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. The stock's fifty day moving average price is $3.68 and its two-hundred day moving average price is $3.63. The company has a market capitalization of $570.79 million, a PE ratio of -0.87, a price-to-earnings-growth ratio of 6.46 and a beta of 1.64.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. The business had revenue of $59.19 million during the quarter, compared to the consensus estimate of $56.20 million. During the same quarter in the previous year, the firm posted $0.08 EPS. The firm's revenue was down 6.8% on a year-over-year basis. Sell-side analysts anticipate that Definitive Healthcare Corp. will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Several hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP grew its holdings in Definitive Healthcare by 5,305.5% in the fourth quarter. Quantbot Technologies LP now owns 17,730 shares of the company's stock worth $73,000 after purchasing an additional 17,402 shares during the last quarter. Wells Fargo & Company MN grew its position in Definitive Healthcare by 27.4% during the fourth quarter. Wells Fargo & Company MN now owns 31,297 shares of the company's stock valued at $129,000 after buying an additional 6,736 shares during the period. Price T Rowe Associates Inc. MD grew its position in Definitive Healthcare by 20.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock valued at $85,000 after buying an additional 3,496 shares during the period. Northern Trust Corp grew its position in shares of Definitive Healthcare by 3.2% in the fourth quarter. Northern Trust Corp now owns 497,279 shares of the company's stock valued at $2,044,000 after purchasing an additional 15,530 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Definitive Healthcare by 6.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company's stock valued at $334,000 after purchasing an additional 4,748 shares during the period. 98.67% of the stock is currently owned by institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.